Kyphoscoliosis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Kyphoscoliosis Market Outlook

Thelansis’s “Kyphoscoliosis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Kyphoscoliosis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Kyphoscoliosis Overview

Kyphoscoliosis is a deviation from the spine's typical curvature in the sagittal and coronal planes, which may involve a rotation of the spinal axis. A lateral deviation in the coronal plane of greater than 10 degrees, as determined by the Cobb angle, is considered adult scoliosis. Postural variation can cause lateral deviations less than 10 degrees. "kyphosis" and "lordosis" describe how the spine curves in the sagittal plane. When looking at the spine laterally, the cervical and lumbar spines exhibit a normal degree of lordosis, or posterior curvature, ranging from 35 to 80 degrees; in contrast, the thoracic spine naturally exhibits a degree of kyphosis, or forward curvature, often between 30 and 50 degrees. The multifactorial etiology of kyphoscoliosis varies according to the patient's demographics. Causes can be divided into three categories: congenital, secondary, and idiopathic. Most cases are due to idiopathic reasons, which are still complex and have an uncertain etiology. Degenerative and senile changes, inflammatory diseases, posttraumatic fractures, iatrogenic post-surgical changes, and recurrent microtraumas from misuse are examples of secondary and disease-related causes. Reversible muscle imbalances that cause the thoracic spine to curve excessively may cause postural thoracic kyphosis. The underlying cause, age, degree of deformity, and presence or absence of neurologic impairments all influence the best course of treatment. Usually, conservative measures are taken to begin treatment, which may advance to the point where surgery is necessary. Kyphoscoliosis in younger patients could be an unintentional finding with minimal to no functional impact. A conservative approach to pain management involves taking NSAIDs.

• Scheuermann's illness, which primarily affects boys and has an incidence of 0.4% to 8% in the USA, is a prevalent cause of juvenile kyphoscoliosis. Typically, children with this disease are between 13 and 16.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: